BioNTech SE
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, BioNTech SE sits in the top decile of US sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count).
BioNTech SE: 53 sponsored US clinical trials, 19 recruiting.
BioNTech SE sponsors 53 registered US clinical trials on ClinicalTrials.gov, 19 of them currently recruiting, and 19 completed. 12 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is COVID-19, with 8 trials.
Top-decile sponsor footprint
BioNTech SE ranks in the top decile of sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 25 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
53 total, page 2 of 2
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
NCT04101357
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
NCT04368728
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
NCT04382898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 15 |
| Phase 3 | 12 |
What is open in the BioNTech SE pipeline
19 recruiting of 53 indexed (36% open); 19 completed (36%).
Phase mix: 12 late (III/IV) vs 40 early (I/II) (early-phase heavy).
Top condition: COVID-19 (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
BioNTech SE: open-pipeline peers nationwide
Peers matched on 53 registered trials and 36% open enrollment, not the therapeutic-area sidebar.
BioNTech SE sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 53 trials (± recruiting share)
- Société des Produits Nestlé (SPN) · 53 trials · 2% recruiting
- Warner Chilcott · 53 trials · 0% recruiting
- W.L.Gore & Associates · 53 trials · 21% recruiting
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
Sponsors near 36% open enrollment (± trial volume)
- Michael J. Fox Foundation for Parkinson's Research · 36% recruiting · 14 trials
- Trustees of Dartmouth College · 35% recruiting · 31 trials
- CooperVision International Limited (CVIL) · 36% recruiting · 11 trials
- Stephanie B. Seminara, MD · 36% recruiting · 11 trials
Related
What to do with this BioNTech SE page
53 registered trials is a research-attention snapshot, not an endorsement of BioNTech SE or any single study.
- 19 of BioNTech SE's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- COVID-19 is the condition BioNTech SE studies most, compare against other sponsors active in the same condition before evaluating a specific study. See COVID-19 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BioNTech SE pipeline card: 53 registered trials from official public datasets.Report a data error.